title: Targeted Immunomodulatory Therapy: An Overview.
abstract: Monoclonal antibodies and other biologic response modifiers have allowed for targeted drug therapy in managing various autoimmune diseases. A number of immune pathways have been exploited in the development of targeted immunomodulatory therapies, including cytokine-directed therapies such as tumor necrosis factor-alpha and interleukins, integrins, B-cells, and co-stimulation modulators. With new targeted therapies in the pipeline, more options are becoming available for treatment of autoimmune diseases. [Full article available at http://rimed.org/rimedicaljournal-2016-12.asp].
authors.affiliation: Clinical Pharmacist Specialist, Ambulatory Care, Department of Pharmacy, Rhode Island Hospital, Providence, RI.
authors.forename: Ashley L
authors.initials: AL
authors.lastname: Lefebvre
authors.affiliation: Ambulatory Care Pharmacy Resident, Department of Pharmacy, Rhode Island Hospital, Providence, RI.
authors.forename: Laura
authors.initials: L
authors.lastname: McAuliffe
mesh_terms: D000911:Antibodies, Monoclonal / Q000145:classification / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000145:classification / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors
keywords: biologic response modifiers; immunomodulatory therapy; monoclonal antibodies